Business Context and Reporting Period
This Form 8-K filing by Gemphire Therapeutics Inc. (not Metavia Inc.) reports a significant executive leadership change effective May 1, 2018. The company is an emerging growth company incorporated in Delaware, focused on life science technology and drug development.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: At least $500,000 annually.
- Signing Bonus: $250,000.
- Annual Cash Bonus: Up to 50% of base salary.
- Stock Options: Granted at an exercise price of $5.56 per share.
Material Changes
Dr. Steven Gullans was appointed as President and Chief Executive Officer, transitioning from his role as Interim President and CEO held since May 2017. He continues to serve as a director. The company entered into a new three-year Employment Agreement with automatic renewal provisions.
Guidance, Outlook, and Risks
Equity Grants and Conditions:
- 150,000 shares vest over 48 months.
- 50,000 shares vest over 48 months, subject to stockholder approval of a plan amendment to increase authorized shares by 300,000.
- 100,000 shares are performance-based, vesting upon specific clinical trial milestones (Phase 3 first patient dose) or stock price targets by December 31, 2019, also subject to stockholder approval.
- Severance includes one year of base salary plus pro-rated bonus and 12 months of medical coverage upon termination without cause.
- Change in control triggers 1.5x salary and bonus plus accelerated vesting of equity awards.
- Two tranches of stock options (150,000 shares total) are contingent on stockholder approval at the May 22, 2018 annual meeting; failure to approve will void these options.
Investor Verification Checklist
- Confirm the outcome of the stockholder vote on the equity plan amendment at the May 22, 2018 annual meeting.
- Review the full Employment Agreement (Exhibit 10.1) for detailed vesting schedules and clawback provisions.
- Verify the company's cash position to ensure it can fund the $250,000 signing bonus and future salary obligations.
- Monitor progress on the Phase 3 clinical trial for gemcabene to assess the vesting of performance-based options.